Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNA5 | P22460 | 14/20 | 0.72 |
| ▸ | KCNK3 | O14649 | 2/20 | 0.69 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.69 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.53 |
| ▸ | NPC1 | O15118 | 2/20 | 0.49 |
| ▸ | RAB9A | P51151 | 2/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2209570 | 0.94 | KCNA5 (0.77) | KCNA5KCNK3KCNA3KCNH2 | |
| SCHEMBL2207891 | 0.89 | KCNA5 (0.66) | KCNA5KCNK3KCNA3SLC6A5 | |
| SCHEMBL12434195 | 0.88 | KCNA5 (0.75) | KCNA5KCNK3KCNA3RAB9AKCNH2 | |
| SCHEMBL2210100 | 0.87 | KCNA5 (0.86) | KCNA5KCNK3KCNA3KCNH2 | |
| SCHEMBL12434460 | 0.86 | KCNA5 (0.69) | KCNA5KCNK3KCNA3NPC1RAB9A | |
| SCHEMBL12434140 | 0.86 | KCNA5 (0.67) | KCNA5KCNK3KCNA3KCNH2 | |
| SCHEMBL12434193 | 0.84 | KCNA5 (0.73) | KCNA5KCNK3KCNA3KCNH2 | |
| SCHEMBL2208671 | 0.84 | KCNA5 (1.00) | KCNA5KCNK3KCNA3 | |
| SCHEMBL12434021 | 0.84 | KCNA5 (0.92) | KCNA5KCNK3KCNA3 | |
| SCHEMBL498662 | 0.82 | KCNA5 (1.00) | KCNA5KCNK3KCNA3KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7982045-B2 | 2′-substituted 1,1′-biphenyl-2-carboxamides, processes for their preparation, their use as medicaments, and pharmaceutical preparations comprising them | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2011-07-19 | — | — | US | disclosed |
| US-7982045-B2 | 2′-substituted 1,1′-biphenyl-2-carboxamides, processes for their preparation, their use as medicaments, and pharmaceutical preparations comprising them | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2011-07-19 | — | — | US | disclosed |
| US-20090192096-A1 | 2'-Substituted 1,1'-Biphenyl-2-Carboxamides, Processes For Their Preparation, Their Use As Medicaments, And Pharmaceutical Preparations Comprising Them | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2009-07-30 | — | — | US | disclosed |
| US-20090192096-A1 | 2'-Substituted 1,1'-Biphenyl-2-Carboxamides, Processes For Their Preparation, Their Use As Medicaments, And Pharmaceutical Preparations Comprising Them | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2009-07-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090192096-A1 | 2'-Substituted 1,1'-Biphenyl-2-Carboxamides, Processes For Their Preparation, Their Use As Medicaments, And Pharmaceutical Preparations Comprising Them | MLLT3, RYR2, CACNA1E | KCNA5 90/4885KCNK3 346/4885KCNA3 83/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.